Литература | References

1. Rotonya M. Carr, Amanke Oranu, and Vandana Khungar. Non-alcoholic fatty liver disease: Pathophysiology and management. MScGastroenterol Clin North Am. 2016 Dec; 45(4): 639-652. doi: 10.1016/j.gtc.2016.07.003

2. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-1402.

3. ICD-11 Implementation or Transition Guide, Geneva: World Health Organization; 2019; License: CCBY-NC-SA3.0IGO.

4. Eslam M, Newsome PN, Anstee QM, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. Journal of Hepatology. (2020), doi: 10.1016/j.jhep.2020.03.039.

5. Eslam M, Sanyal AJ, George J. MAFLD: a consensus driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020 Feb 8. Doi:10.1053/j. gastro.2019.11.312.

6. Yasser Fouad, et al. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver International. 2020;00:1-8.

7. Shi Z., Tuomilehto J., et al. The circadian syndrome predicts cardiovascular disease better than metabolic syndrome in Chinese adults. J Intern Med. 2020 Dec 19. PMID: 31081577. PMCID: PMC6851668. DOI: 10.1111 / joim.12924

8. Ribeiro A., Igual-Perez M.-J., Santos Silva E., Sokal E. M. Childhood fructoholism and fructoholic liver disease. Hepatol Commun. 2019;3:44-51. doi:10.1002/ hep4.1291

9. DiStefano J.K., Shaibi G. Q. The relationship between excessive dietary fructose consumption and paediatric fatty liver disease. Pediatr Obes. 2020 Dec 11: e12759. doi: 10.1111/ ijpo.12759

10. Jegatheesan P, De Bandt J. P. Fructose and NAFLD: the multifaceted aspects of fructose metabolism. Nutrients. 2017;9(3):230. doi: 10.3390/nu9030230

11. Jensen T., Abdelmalek M. F., Sullivan S., et al. Fructose and sugar: a major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68(5):1063-1075. doi: 10.1016/j. jhep.2018.01.019

12. Byrne C.D., Targher G. NAFLD: a multisystem disease. J Hepatol. 2015 Apr;62(1 Suppl): S47-64. doi: 10.1016/j. jhep.2014.12.012. PMID: 25920090.

13. Day C.P., James O. F. Steatohepatitis: a tale of two ‘hits’? Gastroenterology. 1998;114:842-845.

14. Sharma M., Mitnala S., Vishnubhotla R. K., et al. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. Journal of Clinical and Experimental Hepatology. 2015 Jun;5(2):147-158. DOI: 10.1016/j.jceh.2015.02.002

15. Tilg H., Moschen A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836-1846.

16. Buzzetti E., Pinzani M., Tsochatzis E. A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) Metabolism: Clinical and Experimental. 2016, 65(8):1038-1048. DOI: 10.1016/j.metabol.2015.12.012

17. Chelakkot C., Ghim J., Ryu S. H. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 50, 103 (2018). Doi: 10.1038/ s12276-018-0126-x

18. Nier A., et al. Markers of intestinal permeability are already altered in early stages of non-alcoholic fatty liver disease: Studies in children. PLoS One. 2017 Sep 7;12(9): e0183282.

19. Kapil S. et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2016;31:213-221.

20. Philips C.A., Augustine P., Yerol P. K., et al. Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease. J Clin Transl Hepatol. 2020;8(1):87-99. doi:10.14218/ JCTH.2019.00035

21. Wijarnpreecha Karn А. et al. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology. May 2020, Vol. 32, Issue 5, pp. 601-608 doi: 10.1097/MEG.0000000000001541

22. de Faria Ghetti F., et al. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57(3):861-876.

23. Seliverstov P.V., Sitkin S. I., Radchenko V. G., et al. Saccharomyces boulardii modulates the composition of the gut microbiota in patients with non-alcoholic fatty liver disease, thus preventing the progression of the disease. Experimental and Clinical Gastroenterology. 2018;(2):4-18. (In Russ.)

24. Jiang W., et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096.

25. Shen F., et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2017;16(4):375-381.

26. Boursier J, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764-775.

27. Elizabeth K. Speliotes et al. Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits. PLoS Genet. 2011 Mar; 7(3): e1001324.

28. Anstee Q.M., Darlay R., Cockell S., Meroni M., et al. Genomewide association study of non-alcoholic fatty liver and ste-atohepatitis in a histologically characterised cohort. Journal of Hepatology. 2020, Vol. 73, Issue 3, pp. 505-515.

29. Pang, J, Xu, W, Zhang, X, et al. Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017; 46: 175-182. Doi:10.1111/apt.14119

30. Kurtanov K. A., Sydykova L. A., Pavlova N. I., et al. Polymorphism of the adiponutrin gene (PNPLA3) in the indigenous inhabitants of the Republic of Sakha (Yakutia) with type 2 diabetes mellitus. Almanac of Clinical Medicine. 2018;46(3):258-263. (In Russ.) doi: 10.18786/2072-05052018-46-3-258-263 Куртанов Х. А., Сыдыкова Л. А., Павлова Н. И., Филиппова Н. П., Додохов В. В., Апсолихова Г. А., Соловьева Н. А., Дьяконова А. Т., Неустроева Л. М., Варламова М. А., Борисова Н. В. Полиморфизм гена адипонутрина (PNPLA3) у коренных жителей Республики Саха (Якутия), страдающих сахарным диабетом 2-го типа. Альманах клинической медицины. 2018;46(3):258-263.

31. Krolevets T. S., Livzan M. A., Akhmedov V. A., Novikov D. G. Study of PNPLA3 gene polymorphism in patients with non-alcoholic fatty liver disease and various stages of fibrosis. Experimental and Clinical Gastroenterology. 2018;159(11): 24-32. (In Russ.) DOI: 10.31146/1682-8658-ecg-159-11-24-32 Кролевец Т. С., Ливзан М. А., Ахмедов В. А., Новиков Д. Г. Исследование полиморфизма гена PNPLA3 у пациентов с неалкогольной жировой болезнью печени и различной стадией фиброза. Экспериментальная и клиническая гастроэнтерология. 2018;159(11): 24-32. DOI:10.31146/1682-8658-ecg-159-11-24-32.

32. Raikhelson K. L., Kovyazina V. P., Sidorenko D. V. et al. PNPLA gene polymorphism impact on the nonalcoholic fatty liver disease course. RMJ. 2019;12:85-88. Райхельсон К. Л., Ковязина В. П., Сидоренко Д. В. и др. Влияние полиморфизма гена PNPLA3 на течение неалкогольной жировой болезни печени. РМЖ. 2019;12:85-88.

33. Dyakonova A. T., Kurtanov K. A., Pavlova N. I., et al. Polymorphism rs58542926 of the TM6SF2 gene in chronic non-infectious liver diseases in the yakut population. Modern problems of science and education. 2019, no. 6 (in Russ) Avalible at: http://www.scienceeducation.ru/ru/ article/view?id=29334 Дьяконова А. Т., Куртанов Х. А., Павлова Н. И., Соловьева Н. А., Соловьева Ю. А., Филиппова Н. П., Александрова Т. Н. полиморфизм rs58542926 гена TM6SF2 при хронических неинфекционных болезнях печени в якутской популяции // Современные проблемы науки и образования. - 2019. - № 6.; URL: http://www. science education.ru/ru/article/view?id=29334

34. Vajro P., Lenta S., Socha P., Dhawan A., et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2012. Vol.54, pp. 700-713.

35. Vos M.B., Abrams S. H., Barlow S. E., et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):319-334. doi: 10.1097/MPG.0000000000001482. PMID: 28107283; PMCID: PMC5413933.

36. ICD-11 for Mortality and Morbidity Statistics (Version: 09/2020) Available from: https://icd11.ru/ (in Russ.) МКБ-11 (Международная классификация болезней 11 пересмотра) 2020 [Электронный ресурс] URL: https:// icd11 ru/ (дата обращения: 15 01 2021)

37 Kleiner D E, Brunt E M, Natta M Van, Behling C , Contos M J, Oscar, et al Nonalcoholic Steatohepatitis Clinical Research Network Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology. 2005 Jun;41(6):1313-21 . doi: 10.1002/hep .20701.

38. Sorbi D., Boynton J., Lindor K. D. Th e ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating non-alcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999; 94:1018-22.

39. Cerovic I., et al. Alcoholic liver disease/nonalcoholic fatty liver disease index: distinguishing alcoholic from nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2013 Aug;25(8):899-904.

40. Lazebnik L. B., Golovanova E. V., Eremina E. Yu., et al. Clinical recommendations: alcoholic liver disease in adult. Th erapy. 2020, Vol. 6, No. 4 (38), pp. 10-35. (in Russ) doi: 10.18565/therapy.2020.4.10-35 Лазебник Л. Б., Голованова Е. В., Еремина Е. Ю., Кривошеев А. Б., Сас Е. И., Тарасова Л. В., Трухан Д. И., Хлынова О. В., Цыганова Ю. В. Клинические рекомендации: алкогольная болезнь печени у взрослых. Терапия. 2020. Т. 6. № 4 (38). С. 10-35.

41. Maev I.V., Samsonov A. A., Lazebnik L. B. et al. A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. Adv Th er. 2020, no.37, pp. 4627-4640. Doi: 10.1007/s12325-020-01493-w

42. Chalasani N., Younossi Z., Lavine J. E., Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal A. J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan; 67(1):328-357

43. Simona Leoni, Francesco Tovoli, Lucia Napoli, Ilaria Serio, Silvia Ferri, and Luigi Bolondi Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018 Aug 14; 24(30): 3361-3373. doi: 10.3748/wjg.v24. i30.3361

44. Raj Vuppalanchi, Robert J. Gould, Laura A. Wilson, Aynur Unalp-Arida, Oscar W. Cummings,1 Naga Chalasani, Kris V. Kowdley Clinical Significance of Serum Autoantibodies in Patients With NAFLD: Results From The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) / Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Hepatol Int. 2012 Jan; 6(1): 379-385. doi: 10.1007/s12072-011-9277-8

45. Elke M. Hennes, Mikio Zeniya, Albert J. Czaja, Albert Pares, George N. Dalekos, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. International Autoimmune Hepatitis Group. Hepatology. 2008 Jul;48(1):169-76. doi: 10.1002/hep.22322.

46. Karlas T., Petroff D., Sasso M., Fan J. G., Mi Y. Q. Individual patient data meta-analysis of controlled attenuation parameter (cap) technology for assessing steatosis. Hepatol. 2017;66(5):1022-1030. doi: 10.1016/j.jhep.2016.12.022

47. Angulo P., et al. Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015 Aug; 149(2): 389-397.e10. doi: 10.1053/j.gas-tro.2015.04.043

48. Sterling R.K., Lissen E., Clumeck N., et. al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology. 2006;43:1317-1325.

49. Sun W., et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study. Hepatol Res. 2016 Aug;46(9):862-70.

50. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Journal of Hepatology. 2015, vol. 63, j 237-264. DOI: 10.1016/j.jhep.2015.04.006